Early Drug Therapy Does Not Benefit Patients Awaiting Angioplasty

Armen Hareyan's picture
Advertisement

Angioplasty

Administering clot busting and anti platelet agents in patients waiting to receive an angioplasty is not of significant benefit compared to an antiplatelet administered just prior to angioplasty.

Researchers led by Stephen Ellis, M.D., a Cardiologist at Cleveland Clinic, set out to determine if drug therapy could be given prior to angioplasty to begin opening arteries, benefiting patients, without increasing risk and reducing mortality among patients whose angioplasties were delayed.

Advertisement

Angioplasties are a catheter-based procedure commonly used to widen arteries, have been shown to be the best therapy for most heart attack patients, reducing both mortality and associated stroke compared to clot-busting therapy. However, delays until treatment are common as many hospitals do not offer angioplasty and the delays increase the risk of death. During the FINESSE (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events) trial, researchers tested the use of reteplase (a clot-busting agent) in combination with abciximab (a glycoprotein IIbIIIa inhibitor or antiplatelet), and abciximab alone versus primary angioplasty (primary PCI).

Approximately 2,452 patients from 20 countries were enrolled in the trial. All the patients had suffered a heart attack and were referred for angioplasty, but with an expected delay of 1-4 hours. The researchers found that the combination therapy of a reduced dose of reteplase (a thrombolytic) and abciximab (a glycoprotein IIbIIIa inhibitor) did increase measures of blood flow prior to primary angioplasty, but to a lesser extent than expected. In turn, Abciximab just proior to PCI alone did not increase blood flow, according to the research.

In the study, the primary endpoint (a combination of death, cardiogenic shock, heart failure and ventricular fibrillation) at 90 days was seen in 10.7% of patients treated with routine angioplasties, 10.5% with the facilitated abciximab alone approach and 9.8% for the combination facilitated approach. The difference was not statistically significant (p= .55). Bleeding was significantly increased with both new therapies. The results appeared to be true across multiple patient subgroups in the study.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement